预测SCN1A突变婴儿发展为Dravet综合征的临床与遗传因素
该研究分析了182例SCN1A突变携带者,评估性别、首次癫痫发作年龄/发热、癫痫家族史、脑电图和突变类型对预测Dravet综合征与较轻结局的准确性。结果显示首次发作年龄和移码突变与Dravet综合征相关,0-6月组风险为85%,6-12月组为51%,12月后为0%;ROC分析确定第六个月内起病为诊断截点(敏感性83.3%,特异性76.6%)。结论认为起病年龄比突变类型更能预测结局,早期识别和治疗可能限制进展为癫痫性脑病。
要点
- SCN1A突变者中起病年龄比突变类型更能预测Dravet综合征。
- 0-6月起病风险85%,6-12月51%,12月后0%。
- 第六个月内起病为诊断截点,敏感性83.3%,特异性76.6%。
核心结论
- 在SCN1A突变个体中,癫痫起病年龄比突变类型更能预测结局。
- 早期识别和减少婴儿期 prolonged/repeated seizures 的治疗可能限制进展为癫痫性脑病。
研究设计与样本
- 结合性别、首次癫痫发作年龄/发热、癫痫家族史、脑电图和突变类型,分析182例突变携带者(癫痫发作后招募)的预测准确性。
- 计算敏感性、特异性、ROC曲线、诊断比值比、阳性和阴性预测值及联合信息的准确性,并纳入健康亲属的人口学和突变数据。
主要发现
- 关联研究显示首次癫痫发作年龄和移码突变与Dravet综合征相关。
- Dravet综合征风险在0-6月组为85%,6-12月组为51%,12月后为0%。
- ROC分析确定第六个月内起病为进展为Dravet综合征的诊断截点(敏感性83.3%,特异性76.6%)。
关键数值与推荐
- Dravet综合征风险:0-6月组85%,6-12月组51%,12月后0%。
- 第六个月内起病预测Dravet综合征的敏感性83.3%,特异性76.6%。
临床怎么用
- 对SCN1A突变婴儿应关注首次癫痫发作年龄,尤其是6月内起病者Dravet综合征风险高。
- 早期识别并积极治疗以减少婴儿期 prolonged/repeated seizures 可能限制进展为癫痫性脑病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the prognostic value of initial clinical and mutational findings in infants with SCN1A mutations. METHODS: Combining sex, age/fever at first seizure, family history of epilepsy, EEG, and mutation type, we analyzed the accuracy of significant associations in predicting Dravet syndrome vs milder outcomes in 182 mutation carriers ascertained after seizure onset. To assess the diagnostic accuracy of all parameters, we calculated sensitivity, specificity, receiver operating characteristic (ROC) curves, diagnostic odds ratios, and positive and negative predictive values and the accuracy of combined information. We also included in the study demographic and mutational data of the healthy relatives of mutation carrier patients. RESULTS: Ninety-seven individuals (48.5%) had Dravet syndrome, 49 (23.8%) had generalized/genetic epilepsy with febrile seizures plus, 30 (14.8%) had febrile seizures, 6 (3.5%) had focal epilepsy, and 18 (8.9%) were healthy relatives. The association study indicated that age at first seizure and frameshift mutations were associated with Dravet syndrome. The risk of Dravet syndrome was 85% in the 0- to 6-month group, 51% in the 6- to 12-month range, and 0% after the 12th month. ROC analysis identified onset within the sixth month as the diagnostic cutoff for progression to Dravet syndrome (sensitivity = 83.3%, specificity = 76.6%). CONCLUSIONS: In individuals with SCN1A mutations, age at seizure onset appears to predict outcome better than mutation type. Because outcome is not predetermined by genetic factors only, early recognition and treatment that mitigates prolonged/repeated seizures in the first year of life might also limit the progression to epileptic encephalopathy.
引用
- Cetica V, Chiari S, Mei D, et al. Clinical and genetic factors predicting Dravet syndrome in infants with SCN1A mutations. Neurology. 2017. PMID: 28202706. doi:10.1212/WNL.0000000000003716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。